nach oben

Diabetologia

Erschienen in:

01.06.2003 | Article

Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model

verfasst von: T. Ota, T. Takamura, MD PhD, H. Ando, E. Nohara, H. Yamashita, K. Kobayashi

Erschienen in: Diabetologia | Ausgabe 6/2003

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

We investigated the effect of cerivastatin, a statin, on the development of diabetic nephropathy in spontaneously hypertensive rats (SHR) with streptozotocin-induced diabetes.

Methods

Diabetic SHR were given standard chow or chow containing cerivastatin at a dose of 0.1 mg/kg or 1.0 mg/kg for 12 weeks. Effects of cerivastatin on urinary albumin excretion, mesangial expansion, glomerular macrophage infiltration, and the number of anionic sites on the glomerular basement membrane (GBM) were assessed.

Results

Cerivastatin did not affect the blood glucose concentration, blood pressure or serum cholesterol concentration in diabetic SHR. However, cerivastatin treatment caused a dose-dependent decrease of albuminuria and hyperfiltration. At 1.0 mg/kg, cerivastatin inhibited the diabetes-induced expansion of mesangial and tuft areas on histological examination of the kidneys, as well as the loss of anionic sites from the GBM evaluated with polyetyleneimine and the intraglomerular infiltration of ED1-positive macrophages evaluated by immunohistochemistry. Whole-kidney expression of mRNA for MCP-1 and TGF-β, estimated by the real-time quantitative RT-PCR, was increased (both 2.6-fold) in untreated diabetic SHR at 12 weeks. Cerivastatin treatment (1.0 mg/kg) inhibited the up-regulated expression of MCP-1 and TGF-β mRNA (decreased to 48% and 34%, respectively) in diabetic SHR.

Conclusion/interpretation

In this hypertensive model of diabetic nephropathy, cerivastatin decreased albuminuria through suppression of glomerular hyperfiltration, mesangial expansion, and the loss of charge barrier independently of a cholesterol-lowering effect. These preventive effects could be at least partly due to inhibition of macrophage recruitment and activation, and inhibition of TGF-β overexpression.

UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. BMJ 317:703–713PubMed

Mauer SM (1994) Structural-functional correlations of diabetic nephropathy. Kidney Int 45:612–622PubMed

Furuta T, Saito T, Ootaka T et al. (1993) The role of macrophages in diabetic glomerulosclerosis. Am J Kidney Dis 21:480–485PubMed

Klahr S, Schreiner G, Ichikawa I (1988) The progression of renal disease. N Engl J Med 318:1657–1666

Ohta MY, Nagai Y, Takamura T, Nohara E, Kobayashi K (2000) Inhibitory effect of troglitazone on tumor necrosis factor alpha-induced expression of monocyte chmoattractant protein-1 in human mesangial cells. Metabolism 49:163–166PubMed

Oppenheim JJ, Zachariae CO, Mukaida N, Matsushima K (1991) Properties of the novel proinflammatory supergene ''intercrine'' cytokine family. Annu Rev Immunol 9:617–648PubMed

Ando H, Takamura T, Ota T, Nagai Y, Kobayashi K (2000) Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J Pharmacol Exp Ther 294:1043–1046PubMed

Yamashita H, Nagai Y, Takamura T, Nohara E, Kobayashi K (2002) Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat. Metabolism 51:403–408CrossRefPubMed

Weibel ER (1979) Stereological methods: practical methods for biological morphometry. Academic Press, London, pp 162–203

10.

Takamura T, Nohara E, Nagai Y, Kobayashi K (2001) Stage-specific effects of a thiazolidinedione on proliferation, differentiation and PPARγ mRNA expression in 3T3-L1 adipocytes. Eur J Pharmacol 422:23–29CrossRefPubMed

11.

Mogensen CE (1984) Microalbuminuria predicts clinical proteinuria and mortality in maturity-onset diabetes. N Engl J Med 310:356–360PubMed

12.

UK Prospective Diabetes Study Group (1998) Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes: UKPDS 33. Lancet 352:837–853PubMed

13.

Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Anderson S, Arner P, Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group (2001) The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870–878

14.

Fried LF, Orchard TJ, Kasiske BL (2001) Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 59:260–269CrossRefPubMed

15.

Park JK, Muller DN, Mervaala EM et al. (2000) Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects. Kidney Int 58:1420–1430CrossRefPubMed

16.

Ni W, Egashira K, Kataoka C et al. (2001) Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis. Circ Res 89:415–421PubMed

17.

Hostetter TH, Troy JC, Brenner BM (1981) Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int 19:410–415PubMed

18.

Young BA, Johnson RJ, Alpers CE et al. (1995) Cellular events in the evolution of experimental diabetic nephropathy. Kidney Int 47:935–944PubMed

19.

Rovin BH, Tan LC (1992) LDL stimulates mesangial fibronectin and chemoattractant expression. Kidney Int 43:218–225

20.

Ihm CG, Park JK, Hong SP et al. (1998) A high glucose concentration stimulates the expression of monocyte chemotactic peptide 1 in human mesangial cells. Nephron 79:33–37CrossRefPubMed

21.

Banba N, Nakamura T, Matsumura M, Kuroda H, Hattori Y, Kasai K (2000) Possible relation of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int 58:684–690CrossRefPubMed

22.

Aikawa M, Rabkin E, Sugiyama S et al. (2001) An HMG CoA reductase inhibitor, cerivastatin, suppresses growth of macrophage expressing matrix metalloproteinases, and tissue factor in vivo and in vitro. Circulation 103:276–283PubMed

23.

Ueda A, Okuda K, Ohno S et al. (1994) NF-kappa B and Sp1 regulate transcription of the human monocyte chemoattractant protein-1 gene. J Immunol 153:2052–2063PubMed

24.

O'Donnell MP, Kasiske BL, Kim Y, Atluru D, Keane WF (1993) The mevalonate pathway: importance in mesangial cell biology and glomerular disease. Miner Electrolyte Metab 19:173–179PubMed

25.

Goldstein JL, Brown MS (1990) Regulation of the mevalonate pathway. Nature 343:425–430PubMed

26.

Maltese WA (1990) Posttranslational modification of proteins by isoprenoids in mammalian cells. FASEB J 4:3319–3328PubMed

27.

Border WA, Noble NA (1994) Transforming growth factor β in tissue fibrosis. N Engl J Med 331:1286–1292PubMed

28.

Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA (1993) Expression of transforming growth factor-β is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 90:1814–1818PubMed

29.

Sharma K, Ziyadeh FN (1995) Hyperglycemia and diabetic kidney disease: the case for transforming growth factor-β as a key mediator. Diabetes 44:1139–1146PubMed

30.

Sharma K, Jin Y, Guo J, Ziyadeh FN (1996). Neutralization of TGF-β by anti- TGF-β antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45:522–530PubMed

31.

Bollineni JS, Reddi AS (1996) Transforming growth factor-β1 enhances glomerular collagen synthesis in diabetic rats. Diabetes 42:1673–1677

32.

Haneda M, Araki S, Togawa M, Sugimoto T, Isono M, Kikkawa R (1997) Mitogen-activated protein kinase cascade is activated in glomeruli of diabetic rats and glomerular mesangial cells cultured under high glucose conditions. Diabetes 46:847–853PubMed

33.

Schneider A, Panzer U, Zahner G et al. (1999) Monocyte chemoattractant protein-1 mediates collagen deposition in experimental glomerulonephritis by transforming growth factor-β. Kidney Int 56:135–144CrossRefPubMed

34.

Kanwar YS, Farquhar MG (1979) Isolation of glycosaminoglycans (heparan sulfate) from glomerular basement membranes. Proc Natl Acad Sci USA 76:4493–4497PubMed

35.

Kanwar YS, Linker A, Farquhar MG (1980) Increased permeability of the glomerular basement membrane to ferritin after removal of glycosaminoglycans (heparan sulfate) by enzyme digestion. J Cell Biol 86:688–693PubMed

36.

Rosenzweig LJ, Kanwar YS (1982) Removal of sulfated (heparan sulfate) or nonsulfated (hyaluronic acid) glycosaminoglycans results in increased permeability of the glomerular basement membrane to¹²⁵I-bovine serum albumin. Lab Invest 47:177–184PubMed

37.

Kofoed-Enevoldsen A (1992) Inhibition of glomerular glucosaminyl N-deacetylase in diabetic rats. Kidney Int 41:763–767PubMed

38.

Kashihara N, Watanabe Y, Makino H, Wallner EI, Kanwar YS (1992) Selective decreased de novo synthesis of glomerular proteoglycans under the influence of reactive oxygen species. Proc Natl Acad Sci USA 89:6309–6313PubMed

39.

Moriyama T, Kawada N, Nagatoya K et al. (2001) Fluvastatin suppress oxidative stress and fibrosis in the interstitium of mouse kidneys with unilateral ureteral obstruction. Kidney Int 58:2095–2103CrossRef

Titel: Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model
verfasst von: T. Ota
T. Takamura, MD PhD
H. Ando
E. Nohara
H. Yamashita
K. Kobayashi
Publikationsdatum: 01.06.2003
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 6/2003
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-003-1099-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Intervallfasten zur Regeneration des Herzmuskels?

14.05.2024 Herzinfarkt Nachrichten

Die Nahrungsaufnahme auf wenige Stunden am Tag zu beschränken, hat möglicherweise einen günstigen Einfluss auf die Prognose nach akutem ST-Hebungsinfarkt. Darauf deutet eine Studie an der Uniklinik in Halle an der Saale hin.

Klimaschutz beginnt bei der Wahl des Inhalators

14.05.2024 Klimawandel Podcast

Auch kleine Entscheidungen im Alltag einer Praxis können einen großen Beitrag zum Klimaschutz leisten. Die neue Leitlinie zur "klimabewussten Verordnung von Inhalativa" geht mit gutem Beispiel voran, denn der Wechsel vom klimaschädlichen Dosieraerosol zum Pulverinhalator spart viele Tonnen CO₂. Leitlinienautor PD Dr. Guido Schmiemann erklärt, warum nicht nur die Umwelt, sondern auch Patientinnen und Patienten davon profitieren.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Aims/hypothesis

Methods

Results

Conclusion/interpretation

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2003

Distribution of HERV-LTR elements in HLA-DQB1 alleles: comments on the article by Bieda et al.

ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy

Variations in process and outcomes of diabetes care by socio-economic status in Salford, UK

Keratinocyte growth factor and beta-cell differentiation in human fetal pancreatic endocrine precursor cells

Formation of insulin-positive cells in implants of human pancreatic duct cell preparations from young donors